Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease

Summary

Evaluate the tolerability, efficacy and safety of VOS versus Restasis® in subjects with mild to moderate Dry Eye Disease (DED).

Timeline

Start

2018-08-13

Primary completion

2018-11-09

Completion

2018-12-13

Outcome

Missed primary endpoint

registry analysis (superiority test); Voclosporin Ophthalmic Solution (VOS) vs Comparator; p = 0.1491; Mean Difference (Final Values) 4.6 (95% CI -1.7 to 10.9); ANCOVA NCT03597139 ↗

Drugs

Indications